LM22A-4 – (37988-18-4)

LM22A-4 is a synthetic, selective small-molecule partial agonist of TrkB, the main receptor for brain-derived neurotrophic factor (BDNF). Despite its promising neurogenic and neuroprotective properties observed in animal models, LM22A-4 suffers from poor blood-brain-barrier penetration when administered systemically. To circumvent this limitation, researchers have utilized intranasal administration to achieve central nervous system TrkB activation.

In studies, LM22A-4 has demonstrated significant benefits in animal models of neurological conditions. It upregulates osteopontin (OPN) and alkaline phosphatase (ALPase) mRNA expression in a dose-dependent manner and increases osteocalcin (OC) mRNA levels at a concentration of 5 µM. Additionally, LM22A-4 has been shown to stimulate OPN and OC mRNA expression in human cementoblast cells cultured with mineralizing media. In vivo, LM22A-4 reduces tissue injury and apoptosis, as evidenced by decreased TUNEL staining and caspase-3 and Bcl-2 expression, and improves limb function recovery and neurological scores.

A recent study highlighted LM22A-4’s potential in treating pediatric traumatic brain injury (TBI). Acute treatment with LM22A-4 after TBI in mice conferred neuroprotection and preserved myelin integrity, particularly in the corpus callosum and external capsules.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/LM22A-4
https://www.medchemexpress.com/LM22A-4.html
https://www.medkoo.com/products/52548
https://pubmed.ncbi.nlm.nih.gov/33609501/
https://www.sciencedirect.com/science/article/abs/pii/S1567576914000423